NCT06607237View on ClinicalTrials.gov

Evaluation of Safety and Efficacy of DM-28 for Treatment of Moderate to Severe Ocular Dryness

NACompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 26, 2024

Primary Completion Date

January 9, 2025

Study Completion Date

January 9, 2025

Conditions
Dry Eye
Interventions
DEVICE

DM-28

1 drop in each eye, 4 to 6 times per day

Trial Locations (2)

Unknown

Eurofins Dermscan Poland, Gdansk

Tu sie Leczy, Gdansk

Sponsors

Lead Sponsor

Horus Pharma
All Listed Sponsors
collaborator

Eurofins Dermscan Pharmascan

INDUSTRY

lead

Horus Pharma

INDUSTRY

NCT06607237 - Evaluation of Safety and Efficacy of DM-28 for Treatment of Moderate to Severe Ocular Dryness | Biotech Hunter | Biotech Hunter